- Home
- NBIX vs DOCU Comparison
NBIX vs DOCU Comparison
Compare NBIX & DOCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- DOCU
- Stock Information
- Founded
- NBIX 1992
- DOCU 2003
- Country
- NBIX United States
- DOCU United States
- Employees
- NBIX N/A
- DOCU N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- DOCU EDP Services
- Sector
- NBIX Health Care
- DOCU Technology
- Exchange
- NBIX Nasdaq
- DOCU Nasdaq
- Market Cap
- NBIX 14.4B
- DOCU 14.6B
- IPO Year
- NBIX 1996
- DOCU 2018
- Fundamental
- Price
- NBIX $150.87
- DOCU $69.74
- Analyst Decision
- NBIX Strong Buy
- DOCU Hold
- Analyst Count
- NBIX 18
- DOCU 17
- Target Price
- NBIX $172.06
- DOCU $95.62
- AVG Volume (30 Days)
- NBIX 1.0M
- DOCU 2.3M
- Earning Date
- NBIX 10-28-2025
- DOCU 12-04-2025
- Dividend Yield
- NBIX N/A
- DOCU N/A
- EPS Growth
- NBIX 12.44
- DOCU N/A
- EPS
- NBIX 4.19
- DOCU 1.33
- Revenue
- NBIX $2,682,700,000.00
- DOCU $3,095,362,000.00
- Revenue This Year
- NBIX $23.68
- DOCU $9.55
- Revenue Next Year
- NBIX $18.02
- DOCU $6.78
- P/E Ratio
- NBIX $35.78
- DOCU $52.25
- Revenue Growth
- NBIX 19.61
- DOCU 8.29
- 52 Week Low
- NBIX $84.23
- DOCU $66.35
- 52 Week High
- NBIX $157.67
- DOCU $107.86
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- DOCU 43.93
- Support Level
- NBIX $133.62
- DOCU $68.31
- Resistance Level
- NBIX $157.67
- DOCU $74.25
- Average True Range (ATR)
- NBIX 4.58
- DOCU 2.18
- MACD
- NBIX 0.98
- DOCU 0.19
- Stochastic Oscillator
- NBIX 67.98
- DOCU 22.91
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.